ALGN

Business profile & competitive position

Align Technology, Inc. operates in the Healthcare sector, specifically the Medical - Devices industry. The company designs, manufactures, and markets the Invisalign System of clear aligners to treat malocclusion, plus Vivera retainers, iTero intraoral scanners, related services, and exocad CAD/CAM software for dental labs. These products are tied together by the Align Digital Platform, an end-to-end digital workflow that connects orthodontists, general dental practitioners, dental laboratories, and patients.

The revenue mix is lopsided toward aligners: in 2025, the Clear Aligner segment generated roughly 80% of worldwide net revenues, while Systems and Services contributed the remaining ~20%. More than 95% of Invisalign System prescription orders are now submitted via digital scan, which lowers turnaround time, improves treatment accuracy, and reduces reliance on physical polyvinyl-siloxane impressions.

On the profitability side, Align’s net margin is 10.0% and its ROE is 10.1%. Those figures suggest a business with real product differentiation and a sticky digital ecosystem, but not a deep, cash-generating moat. A 10.0% net margin is healthy for a device maker investing heavily in sales-force expansion and scanner placement, while a 10.1% ROE is roughly in line with a typical cost-of-equity benchmark rather than the high-teens returns investors usually associate with a dominant medical-device franchise. The installed base of iTero scanners and the clinician training behind Invisalign create switching costs, yet the numbers confirm that competition from traditional wires-and-brackets, direct-to-consumer aligner brands, and pricing pressure in international markets still weigh on the bottom line.

Financial posture

Align currently carries an $11.4 billion market capitalization, trades at a P/E of 27.5, and sports a beta of 1.64. The stock price most recently closed at $158.635, with an RSI of 41.8 and a 50-day EMA of $168.14. That combination tells a fairly clear story: the market is pricing in meaningful growth, but the stock has been under short-term pressure and is trading below its 50-day exponential moving average.

A P/E near 27.5 on a 10.0% net margin and 10.1% ROE implies the valuation is relying on future margin expansion, top-line volume growth, and continued conversion of orthodontic case starts from metal brackets to clear aligners. The beta of 1.64 signals that Align tends to move about 64% more than the overall market, which is consistent with a discretionary-medical product whose demand fluctuates with consumer confidence, teen household spending, and dental-office traffic. Recent price weakness—down close to the 50-day EMA and in the low-40s on RSI—reflects that sensitivity rather than a value conclusion.

Strategic priorities & outlook

According to Align’s most recent SEC 10-K filing, the company’s near-term operational focus has four explicit pillars:

• Establish clear aligners as the principal malocclusion treatment and the Invisalign System as the preferred choice among orthodontists, general practitioners, and patients globally.
• Make the iTero intraoral scanner the default scanning technology for digital dental scans.
• Make exocad CAD/CAM software the restorative solution of choice for dental laboratories.
• Increase share of the orthodontic case-start market versus wires and brackets, especially among teens, while expanding the overall market for digital orthodontics among adults.

Operationally, this translates into continued investment in the sales force, in-office scanner placements, and software integration. A notable recent move is the January 2024 acquisition of Cubicure, which Align bought to scale direct 3D-printing capabilities. The company has already begun limited manufacturing of certain appliances and plans to pilot additional devices—including retainers and certain prefabricated attachments—in limited releases during 2026. These initiatives carry execution risk and will likely keep operating expenses elevated, but they also show Align trying to extend its moat beyond aligner brand recognition into manufacturing and lab workflow control.

Macro & geopolitical exposure

As a Medical - Devices company, Align faces the industry’s standard macro risk matrix. Regulatory clearance and reimbursement decisions from the FDA, EMA, and other health authorities can affect product launches, labeling, and marketing claims. Medical-device tariffs or broader trade-policy shifts can raise costs on scanners, aligner materials, and 3D-printing inputs, particularly for a supply chain that spans North America, Europe, and Asia. Currency translation matters because Align books revenue in many local currencies, so a strong U.S. dollar can compress reported results even when local-case volumes are stable.

On the demand side, clear aligners sit at the intersection of healthcare and consumer discretion. Teen and adult orthodontic case starts are sensitive to household disposable income, employment trends, dental-insurance coverage, and dentist capacity. A slowdown in consumer spending or a tightening of credit conditions can delay elective orthodontic treatment. Input-cost volatility—resins, plastics, and scanner components—also feeds into gross-margin pressure. None of these factors are unique to Align, but they are all relevant to a global medical-device business whose biggest revenue driver depends on patients choosing an elective, higher-priced solution over traditional braces.

Recent developments

Recent news flow has been a mix of governance, institutional activity, and price commentary:

• August 31, 2026 — businesswire.com: Quentin Blackford was announced as a new member of Align’s Board of Directors.
• August 31, 2026 — defenseworld.net: Canada Pension Plan Investment Board disclosed an acquisition of 26,510 shares of Align Technology.
• August 28, 2026 — zacks.com: A headline asked why Align had fallen 8.4% since its last earnings report.
• August 17, 2026 — gurufocus.com: Another headline noted the stock was down 5.6% and highlighted a quantitative GF Score of 89/100.

These items do not resolve the bull-bear debate by themselves. The board addition may bring operational expertise, and the CPPIB purchase shows at least one large institutional buyer stepping in near current levels. The Zacks and GuruFocus headlines, however, confirm that the post-earnings price action has disappointed bulls despite an inline-to-positive quarter. The GF Score of 89 is a third-party quantitative observation, not a directional verdict, but it does signal that the stock’s underlying fundamentals still screen relatively well on a factor basis even after the pullback.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Align has beaten earnings expectations 7 out of 8 times, for an 88% beat rate, with an average earnings surprise of +4.7%. The average 5-day move after earnings has been +5.26%, classified as an upward drift. On the surface, that looks like a clean pattern: Align usually beats, and the stock usually drifts higher.

The reality is more nuanced. In the most recent quarters, the post-earnings reaction has not reliably followed the direction or size of the EPS surprise:

• July 29, 2026: Actual EPS of $2.64 vs. the $2.62 estimate, a +0.8% beat; the stock fell -3.7% the next day and -2.92% over the following five sessions.
• April 29, 2026: Actual EPS of $2.58 vs. the $2.30 estimate, a +12.2% beat; the stock dropped -1.34% the next day and -2.5% over five sessions.
• February 4, 2026: Actual EPS of $3.29 vs. the $2.99 estimate, a +10.0% beat; the stock jumped +8.88% the next day and +22.45% over five sessions.
• October 29, 2025: Actual EPS of $2.61 vs. the $2.40 estimate, an +8.8% beat; the stock rose +4.94% the next day and +4.02% over five sessions.

This split record illustrates that the headline EPS beat is not the sole driver of the post-earnings move. Guidance, case-start volumes, teen vs. adult mix, scanner utilization, margin commentary, and broader sector sentiment can all override a positive EPS print. The company’s beta of 1.64 also amplifies those cross-currents. Looking ahead, Align is scheduled to report next on October 28, 2026, after the close, with the unofficial EPS consensus at $2.78.

For a deeper look at how professional analysts and institutional models currently view Align Technology, readers should consult the full institutional verdict page, which summarizes price-target distributions, recommendation changes, and sector context beyond the figures covered here.